Beneficial Effects of Colchicine for Moderate to Severe COVID-19: An Interim Analysis of a Randomized, Double-blinded, Placebo Controlled Clinical Trial
|
Design
|
Single-center, randomized, double-blinded, placebo-controlled trial
N=35
|
Objective
|
To evaluate the use of colchicine for the treatment of hospitalized patients with moderate to severe COVID-19
|
Study Groups
|
Placebo (n=18)
Colchicine (n=17)
|
Inclusion Criteria
|
Patients with moderate to severe COVID-19 diagnosed by RT-PCR in nasopharyngeal swab specimens and lung CT scan involvement compatible with COVID-19 pneumonia; older than 18 years old; body weight >50 kg; normal levels of serum Ca2+ and K+; negative serum or urinary β-HCG in females under 50 years
|
Exclusion Criteria
|
Mild COVID-19 or in need of ICU admission; diarrhea resulting in dehydration; known allergy to colchicine; diagnosis of porphyria, myasthenia gravis or uncontrolled arrhythmia at enrollment; immunosuppressive chemotherapy; regular use of digoxin, verapamil, amiodarone, or protease inhibitor; chronic liver disease with hepatic failure
|
Methods
|
Participants were randomized 1:1 to receive either colchicine or place in addition to standard of care for moderate-to-severe COVID-19.
Patients in the colchicine arm received 0.5 mg TID for 5 days, then 0.5 mg BID for 5 days; if bodyweight ≥80 kg, the first dose was 1.0 mg. If a patient had chronic kidney disease with glomerular filtration rate <30 mL/min/1.73 m2, the dose was reduced to 0.25 mg TID for 5 days, then 0.25 BID for 5 days regardless of body weight.
Patients were also given azithromycin 500 mg once daily for 7 days; hydroxychloroquine 400 mg BID for 2 days, then 400 mg once daily for 8 days; and unfractionated heparin 5000 IU TID until the end of hospitalization. Methylprednisolone 0.5 mg/kg/day for 5 days could be added if oxygen supplementation was 6 L/min or more.
Study medication was discontinued when a patient was admitted to the intensive care unit. Patients were evaluated daily and blood collected on days zero, 2, 4, and 7 if discharge did not occur before.
|
Duration
|
April 11 to July 6, 2020
Treatment: 10 days
|
Outcome Measures
|
Primary: time of need for supplemental oxygen; time of hospitalization; need for admission and length of stay in ICU; death rate and causes of mortality
Secondary: measures of serum CRP, serum LDH and relation neutrophil to lymphocyte of peripheral blood samples from day zero to day 7; the number, type, and severity of adverse events; frequency of interruption of the study protocol due to adverse events; and frequency of QT interval above 450 ms.
|
Baseline Characteristics
|
|
Placebo (n=18)
|
Colchicine (n=17)
|
P-value |
Age, years (IQR)
|
53.5 (35.5-65.5) |
48.0 (41.5-64.0) |
0.94 |
Male
|
5 (27.8%) |
9 (52.9%) |
0.17 |
Body mass index, kg/m2 (IQR) |
30.6 (26.8-34.1) |
33.9 (30.0-09.9) |
0.21 |
Time of symptoms, days (IQR) |
7 (6.5-9.0) |
9 (7.0-10.5) |
0.08 |
Fatigue*
|
5 (28%) |
12 (70%) |
0.01 |
Creatinine (IQR) |
0.70 (0.57-0.81) |
0.90 (0.65-0.99) |
0.03 |
Received methylprednisolone |
7 (39%) |
7 (41%) |
1.00 |
*other common symptoms (e.g., fever, cough, myalgia, diarrhea) did not differ significantly at baseline.
IQR=interquartile range
|
Results
|
|
Placebo (n=18) |
Colchicine (n=17)
|
p-Value
|
Time of supplemental O2, days (IQR)
|
7.0 (3.0-8.5) |
3.0 (1.5-6.5) |
0.02 |
Time of hospitalization, days (IQR)
|
8.5 (5.5-11.0)
|
6.0 (4.0-8.5) |
0.03 |
C-reactive protein (IQR)
Baseline
Day 7
|
8.2 (5.5-14.3)
2.2 (0.9-2.4)
|
7.8 (5.6-10.3)
0.4 (0.3-0.4)
|
0.0001 |
Neutrophil to lymphocyte (IQR)
Baseline
Day 7
|
3.4 (2.2-6.2)
3.5 (1.6-8.2)
|
2.8 (2.4-4.4)
1.5 (1.3-5.6)
|
0.67 |
Lactate dehydrogenase (IQR)
Baseline
Day 7
|
317 (262-433)
213 (195-313)
|
339 (274-474)
259 (228-311)
|
0.004 |
One patient from each group was admitted to the ICU; the length of stay in the ICU was 12 and 11 days, respectively. No patients died.
|
Adverse Events
|
There were more patients in the colchicine group compared to the placebo group that had new or worsened diarrhea at 6% vs 24%, respectively.
No patient had a QT interval above 450 ms.
|
Nosocomial pneumonia was 11% in the placebo group vs 12% in the colchicine group.
|
Study Author Conclusions
|
Patients who received colchicine in this randomized, double-blinded, placebo-controlled clinical trial presented better evolution in terms of the need for supplemental oxygen and the length of hospitalization. Serum CRP was a laboratory marker of clinical improvement. Colchicine was safe and well-tolerated.
|
InpharmD Researcher Critique
|
The study was conducted at one Brazilian center and the sample size was very small. The majority of the patient population were obese women, making it difficult to apply the results to the general population. The exclusion criteria restricted cardiovascular drugs, however, this was due to the drugs impairing colchicine metabolism or excretion and the effects they might have in combination with hydroxychloroquine and azithromycin.
While this pilot study shows promising, hypothesis-generating results, a larger trial is needed to see if these results are valid and apply to a more generalized population.
|